CalciMedica, Inc. Common Stock (CALC) Stock Price
CALCStock
$1.04−93.60%52W
Market Cap$7.10M
P/E—
PEG Ratio—
Div yield—
Beta0.82
CALC Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-76.36%
Price vs S&P 500 (4W)-42.76%
VGM Score10.23
CALC Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$1.45 | -$2.25 | -55.17%(-$0.80) | |
| Q1 2026 | -$1.40 | $1.50 | +207.14%(+$2.90) | |
| Q4 2025 | -$2.06 | -$3.45 | -67.27%(-$1.39) | |
| Q3 2025 | -$2.06 | -$2.60 | -26.06%(-$0.54) | |
| Q2 2025 | -$1.75 | -$2.00 | -14.29%(-$0.25) |
CALC Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.10
4.10
4.00
4.10
Industry Peers — Pharmaceuticals(574)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|---|---|---|
CALCCalciMedica, Inc. Common Stock | — | — | F | — | — | — | — | $1.04 |
| LLYEli Lilly & Co. | D | B | A | 14.9x | 49.6% | 83.4% | 27.6% | $1257.03 |
| JNJJohnson & Johnson | D | C | B | 6.2x | 7.8% | 67.7% | 14.9% | $255.56 |
| ABBVABBVIE INC. | D | C | A | 7.8x | 10.4% | 72.8% | -2.9% | $285.42 |
| MRKMerck & Co., Inc. | D | C | A | 5.4x | 4.6% | 77.3% | 21.2% | $145.95 |
| NVSNovartis AG | C | C | B | 4.9x | 3.3% | 75.0% | 15.3% | $150.62 |
| AZNAstraZeneca PLC | C | B | B | 4.3x | 8.6% | 81.3% | 21.9% | $165.41 |
| ABTAbbott Laboratories | C | C | B | 3.9x | 8.1% | 56.8% | 8.2% | $104.89 |
| NVONovo-Nordisk A/S | B | C | C | 3.5x | 5.6% | 80.7% | 20.7% | $38.83 |
| PFEPfizer Inc. | C | D | A | 2.6x | -0.2% | 74.7% | -3.5% | $29.58 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | 10.1x | 10.2% | 86.0% | 8.3% | $499.74 |
About CalciMedica, Inc. Common Stock
CalciMedica is a clinical-stage biopharmaceutical company developing treatments for serious inflammatory and immune-mediated diseases. Its lead candidate, Auxora, is a CRAC channel inhibitor designed to reduce inflammation and cellular damage in organs including the pancreas, lungs, and kidneys. Preclinical studies suggest potential therapeutic benefit for conditions driven by inflammatory and immune dysfunction.